DVA vs REGN · P/E 14, rev $12.82B vs P/E 14, rev $14.34B
DaVita HealthCare Partners Inc (DVA) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
DaVita HealthCare Partners Inc (DVA) is a medical care facilities company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported DVA revenue for 2024-12-31 was $12.82B. Net income was $1.25B. Revenue was up 5.6% from 2023-12-31 to 2024-12-31. DVA currently screens at market cap $10.77B and trailing P/E 14.1.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
DVA currently screens at market cap $10.77B and trailing P/E 14.1. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the DVA and REGN stock pages for the full models.
Not investment advice.